Markku Nissinen
Overview
Explore the profile of Markku Nissinen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
188
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sahlman P, Nissinen M, Puukka P, Jula A, Salomaa V, Mannisto S, et al.
J Gastroenterol Hepatol
. 2019 Jul;
35(2):291-298.
PMID: 31260143
Background And Aim: Liver disease is traditionally categorized as alcoholic and non-alcoholic. We studied various risk factors predictive of advanced non-viral liver disease in general population and analyzed the interaction...
2.
Koivusalo A, Mutanen A, Nissinen M, Gylling H, Pakarinen M
J Pediatr Gastroenterol Nutr
. 2019 Jun;
69(2):138-144.
PMID: 31169656
Objectives: We elucidated pathophysiology of pediatric gallstone disease by assessing liver expression of bile transporters in relation to bile acids and surrogates of cholesterol absorption and synthesis in serum and...
3.
Sahlman P, Nissinen M, Simonen P, Farkkila M
Lipids
. 2018 Apr;
53(3):323-334.
PMID: 29663389
Severe alcoholic hepatitis (AH) is a life-threatening condition lacking good serologic markers to tailor treatment and predict recovery. We examined the cholesterol metabolism in severe AH to explore prognostic markers...
4.
Sahlman P, Nissinen M, Pukkala E, Farkkila M
Scand J Gastroenterol
. 2016 May;
51(8):961-6.
PMID: 27181618
Objective: We studied the incidence of severe ALD requiring hospitalization in Finland, and survival and causes of death among the ALD patients. Methods: A cohort of 11,873 persons (8796 men...
5.
Hukkinen M, Mutanen A, Nissinen M, Merras-Salmio L, Gylling H, Pakarinen M
JPEN J Parenter Enteral Nutr
. 2016 Mar;
41(6):1014-1022.
PMID: 26962062
Background: Parenteral plant sterols (PSs) are considered hepatotoxic; however, liver PSs and their associations with liver injury in patients with intestinal failure (IF) have not been reported. Materials And Methods:...
6.
Sahlman P, Nissinen M, Pukkala E, Farkkila M
Int J Cancer
. 2016 Jan;
138(11):2616-21.
PMID: 26756434
Both alcohol abuse and liver cirrhosis are known risk factors for various cancers. This article was aimed to assess the long-term risk of malignancies among patients with severe alcoholic liver...
7.
Molander P, Farkkila M, Ristimaki A, Salminen K, Kemppainen H, Blomster T, et al.
J Crohns Colitis
. 2014 Jul;
9(1):33-40.
PMID: 25052347
Background And Aims: This prospective multicenter study examined whether elevated fecal calprotec tin (FC) concentrations after stopping TNFα-blocking therapy can predict clinical or endoscopic relapse. In addition, we evaluated the...
8.
Molander P, Farkkila M, Salminen K, Kemppainen H, Blomster T, Koskela R, et al.
Inflamm Bowel Dis
. 2014 May;
20(6):1021-8.
PMID: 24798636
Background: Few data are available on the disease course in patients with inflammatory bowel disease (IBD) in deep remission after discontinuing tumor necrosis factor α (TNFα)-blocking therapy. In this prospective...
9.
Molander P, Sipponen T, Kemppainen H, Jussila A, Blomster T, Koskela R, et al.
J Crohns Colitis
. 2012 Nov;
7(9):730-5.
PMID: 23182163
Background And Aims: Deep remission, meaning clinical remission with mucosal healing (MH), with anti-tumor necrosis factor-alpha (TNF-α) agents is a new target for therapy in inflammatory bowel disease (IBD). Our...
10.
Nissinen M
Duodecim
. 2011 May;
127(8):785-92.
PMID: 21568106
In addition to drug interactions (e.g. with clopidogrel), PPI therapy has been suggested to have--particularly in long term--undesirable effects on gastric epithelium, infection risk, bone strength, and vitamin and mineral...